Abstract: Therapeutic protein-drug conjugates comprising annexins conjugated to drug payloads for targeting stressed human cells (e.g., cancer cells), bacterial cells, fungal cells, or parasitic cells which express phosphatidylserine. The protein-drug conjugates generally contain multiple drug molecules per annexin molecule. The annexin binds to the surface of cells, but is also endocytosed efficiently, thereby delivering the drug to the cytoplasm of the target cell.

Abstract: A method, composition, and kit for treating a malarial infection in a subject by using an enzyme conjugate comprising a variant cystathione-gamma-lyase and a targeting ligand which binds to erythrocytes infected with Plasmodium pathogens. The variant cystathione-gamma-lyase has methioninase activity. Also disclosed is a method of treating Plasmodium-infected blood by exposing the infected blood with the enzyme conjugate.

Abstract: Gold nanoparticles are conjugated to phosphatidylserine-specific ligands for targeting and binding to surface-exposed phosphatidylserine on tumor cells and tumor vasculature. The ligand may be an annexin (e.g., annexin V). Tumor contrast is significantly increased using the targeted gold nanoparticles. Breast cancer tumors as small as 4 mm, for example, were detectable via computed tomography (CT) within 4 hours after injection of the conjugates, demonstrating usefulness of the conjugates as imaging agents. The targeted gold nanoparticle conjugate may further have a drug conjugated thereto that can be used therapeutically, for example, for cancer treatment. The gold nanoparticle conjugates can also be used for photothermal therapy and can be used in concert with an X-ray radiation treatment for cancer treatment.

Abstract: A method, composition, and kit for treating a malarial infection in a subject by using an enzyme conjugate comprising a variant cystathione-gamma-lyase and a targeting ligand which binds to erythrocytes infected with Plasmodium pathogens. The variant cystathione-gamma-lyase has methioninase activity. Also disclosed is a method of treating Plasmodium-infected blood by exposing the infected blood with the enzyme conjugate.

Abstract: A method and composition for treating a cancerous tumor in a subject by targeting the tumor's vasculature using an enzyme conjugate comprising a ligand which binds to endothelial cells in the tumor vasculature and converts a prodrug administered to the subject into an anticancer drug in the tumor vasculature.

Abstract: Organo-transition metal complexes possess anti-viral inhibitory activity against influenza A, including the S3 IN mutant. The organo-transition metal complexes include a transition metal and at least one ligand based on the structure of an M2 proton channel blocker. Compounds and pharmaceutical compositions are useful for treating viruses such as influenza A.

Abstract: Compositions for detecting and/or destroying cancer tumors and/or cancer cells via photodynamic therapy are disclosed, as well as methods of use thereof. The compositions comprise a linking protein or peptide attached to or otherwise physically associated with a carbon nanotube to form a targeted protein-carbon nanotube complex.

Abstract: A method and composition for treating a cancerous tumor in a subject by targeting the tumor's vasculature using an enzyme conjugate comprising a ligand which binds to endothelial cells in the tumor vasculature and converts a prodrug administered to the subject into an anticancer drug in the tumor vasculature.

Abstract: Methods of treating cancer by targeting tumor vasculature using an enzyme prodrug cancer therapy treatment are provided.

Abstract: Compositions for detecting and/or destroying cancer tumors and/or cancer cells via photodynamic therapy are disclosed, as well as methods of use thereof. The compositions comprise a linking protein or peptide attached to or otherwise physically associated with a carbon nanotube to form a targeted protein-carbon nanotube complex.

Abstract: The present invention is a method for detecting and destroying cancer tumors. The method is based on the concept of associating a linking protein or linking peptide such as, but not limited to, annexin V or other annexins to carbon nanotubes such as single-walled carbon nanotubes (SWNTs) to form a protein-CNT complex. Said linking protein or peptide can selectively bind to cancerous cells, especially tumor vasculature endothelial cells, rather than to healthy ones by binding to cancer-specific external receptors such as anionic phospholipids including phosphatidylserine expressed on the outer surfaces of cancer cells only. Irradiation of bound CNTs with one or more specific electromagnetic wavelengths is then used to detect and destroy those cells to which the CNTs are bound via the linking protein or peptide thereby destroying the tumor or cancer cells and preferably an immunostimulant is provided to the patient to enhance the immune response against antigens released from the tumor or cancer cells.

Abstract: A method for detecting and/or destroying cancer tumors is based on the concept of associating a linking protein or linking peptide to carbon nanotubes to form a protein-carbon nanotube complex.

Abstract: A request for content is received at a content filter of a computer system, and a determination is made, based on a referrer included in the request, regarding a root site directly or indirectly associated with the request. Thereafter, the content is permitted or not permitted according to whether or not the root site is a permitted site and a site associated with the content is categorized in a semantically equivalent content category with the root site. The determination regarding the root site may involve consulting a referrer chain cache storing lists of referrers which associate referring Web sites with root sites from which referrals originate.

Abstract: Conjugates for use in an enzyme prodrug cancer therapy treatment are provided.

Abstract: Chimeric proteins comprising soluble Tissue Factor (sTF) and another subunit (e.g., annexin V) are described. The proteins promote blood clotting and/or inhibit cancer by targeting sTF to specific receptors such as phosphatidylserine (PS) on activated cells. These chimeric proteins are useful in treating patients with excessive bleeding due to inborn problems, drug therapy, trauma or surgery and/or as an anti-cancer therapy, for example by causing blood vessels feeding cancers to become clotted, thereby preventing adequate flow of blood to a tumor, which in turn will lead to tumor inhibition and death or may be used in a therapy to cause clotting within blood vessels that pose a threat in the subject in non-cancerous conditions.

Abstract: The present invention is a method for detecting and destroying cancer tumors. The method is based on the concept of associating a linking protein or linking peptide such as, but not limited to, annexin V or other annexins to carbon nanotubes such as single-walled carbon nanotubes (SWNTs) to form a protein-CNT complex. Said linking protein or peptide can selectively bind to cancerous cells, especially tumor vasculature endothelial cells, rather than to healthy ones by binding to cancer-specific external receptors such as anionic phospholipids including phosphatidylserine expressed on the outer surfaces of cancer cells only. Irradiation of bound CNTs with one or more specific electromagnetic wavelengths is then used to detect and destroy those cells to which the CNTs are bound via the linking protein or peptide thereby destroying the tumor or cancer cells and preferably an immunostimulant is provided to the patient to enhance the immune response against antigens released from the tumor or cancer cells.

Abstract: A conjugate is disclosed herein, wherein the conjugate includes a ligand having the ability to specifically and stably bind to an external receptor or binding site on a tumor vasculature endothelial cell, wherein the external receptor or binding site is specific for tumor vasculature endothelial cells. The conjugate also includes an anticancer agent that is selectively toxic to cancer cells operatively attached to the ligand. The anticancer agent may be L-methioninase. Pharmaceutical compositions comprising the conjugate are also disclosed, as well as methods of treating a cancer tumor or cancer cells with a therapeutically effective amount of the conjugate.

Abstract: The present invention is a method for detecting and destroying cancer tumors. The method is based on the concept of associating a linking protein or linking peptide such as, but not limited to, annexin V or other annexins to single-walled carbon nanotubes (SWNT) to form a protein-SWNT complex. Said linking protein or peptide can selectively bind to cancerous cells, especially tumor vasculature endothelial cells, rather than to healthy ones by binding to cancer-specific external receptors such as anionic phospholipids including phosphatidylserine expressed on the outer surfaces of cancer cells only. Irradiation of bound SWNTs with one or more specific electromagnetic wavelengths is then used to detect and destroy those cells to which the SWNTs are bound via the linking protein or peptide thereby destroying the tumor or cancer cells and preferably an immunostimulant is provided to the patient to enhance the immune response against antigens released from the tumor or cancer cells.

Abstract: Chimeric proteins comprising soluble Tissue Factor (sTF) and another subunit (e.g., annexin V) are described. The proteins promote blood clotting and/or inhibit cancer by targeting sTF to specific receptors such as phosphatidylserine (PS) on activated cells. These chimeric proteins are useful in treating patients with excessive bleeding due to inborn problems, drug therapy, trauma or surgery and/or as an anti-cancer therapy, for example by causing blood vessels feeding cancers to become clotted, thereby preventing adequate flow of blood to a tumor, which in turn will lead to tumor inhibition and death or may be used in a therapy to cause clotting within blood vessels that pose a threat in the subject in non-cancerous conditions.

Abstract: The present invention is a method for detecting and destroying cancer tumors. The method is based on the concept of associating a linking protein or linking peptide such as, but not limited to, annexin V or other annexins to single-walled carbon nanotubes (SWNT) to form a protein-SWNT complex. Said linking protein or peptide can selectively bind to cancerous cells, especially tumor vasculature endothelial cells, rather than to healthy ones by binding to cancer-specific external receptors such as anionic phospholipids including phosphatidylserine expressed on the outer surfaces of cancer cells only. Irradiation of bound SWNTs with specific wavelength is then used to detect and destroy those cells to which the SWNTs are bound via the linking protein or peptide thereby destroying the tumor or cancer cells.